NASDAQ:CDMOP

Avid Bioservices Competitors

$25.06
0.00 (0.00 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$25.06
Now: $25.06
$25.06
50-Day Range
$25.03
MA: $26.66
$31.36
52-Week Range
$21.00
Now: $25.06
$31.95
Volume400 shs
Average Volume11,022 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend Yield9.49%
BetaN/A

Competitors

Avid Bioservices (NASDAQ:CDMOP) Vs. ABCL, SANA, ABCM, SEER, NUVB, and IBRX

Should you be buying CDMOP stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Avid Bioservices, including AbCellera Biologics (ABCL), Sana Biotechnology (SANA), Abcam (ABCM), Seer (SEER), Nuvation Bio (NUVB), and ImmunityBio (IBRX).

Avid Bioservices (NASDAQ:CDMOP) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Profitability

This table compares Avid Bioservices and AbCellera Biologics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Avid BioservicesN/AN/AN/A
AbCellera BiologicsN/AN/AN/A

Earnings & Valuation

This table compares Avid Bioservices and AbCellera Biologics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avid BioservicesN/AN/AN/AN/AN/A
AbCellera BiologicsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Avid Bioservices and AbCellera Biologics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Avid Bioservices0000N/A
AbCellera Biologics00503.00

AbCellera Biologics has a consensus target price of $52.80, suggesting a potential upside of 82.07%. Given AbCellera Biologics' higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than Avid Bioservices.

Summary

AbCellera Biologics beats Avid Bioservices on 2 of the 2 factors compared between the two stocks.

Sana Biotechnology (NASDAQ:SANA) and Avid Bioservices (NASDAQ:CDMOP) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Sana Biotechnology and Avid Bioservices, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sana Biotechnology02202.50
Avid Bioservices0000N/A

Sana Biotechnology presently has a consensus target price of $40.00, suggesting a potential upside of 57.67%. Given Sana Biotechnology's higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than Avid Bioservices.

Profitability

This table compares Sana Biotechnology and Avid Bioservices' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sana BiotechnologyN/AN/AN/A
Avid BioservicesN/AN/AN/A

Valuation and Earnings

This table compares Sana Biotechnology and Avid Bioservices' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sana BiotechnologyN/AN/AN/AN/AN/A
Avid BioservicesN/AN/AN/AN/AN/A

Summary

Sana Biotechnology beats Avid Bioservices on 2 of the 2 factors compared between the two stocks.

Abcam (NASDAQ:ABCM) and Avid Bioservices (NASDAQ:CDMOP) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Abcam and Avid Bioservices, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abcam04302.43
Avid Bioservices0000N/A

Abcam presently has a consensus price target of $22.00, indicating a potential upside of 12.02%. Given Abcam's higher probable upside, analysts clearly believe Abcam is more favorable than Avid Bioservices.

Profitability

This table compares Abcam and Avid Bioservices' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbcamN/AN/AN/A
Avid BioservicesN/AN/AN/A

Earnings and Valuation

This table compares Abcam and Avid Bioservices' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbcamN/AN/AN/AN/AN/A
Avid BioservicesN/AN/AN/AN/AN/A

Summary

Abcam beats Avid Bioservices on 2 of the 2 factors compared between the two stocks.

Seer (NASDAQ:SEER) and Avid Bioservices (NASDAQ:CDMOP) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Valuation and Earnings

This table compares Seer and Avid Bioservices' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SeerN/AN/AN/AN/AN/A
Avid BioservicesN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings for Seer and Avid Bioservices, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seer02202.50
Avid Bioservices0000N/A

Seer presently has a consensus price target of $68.00, indicating a potential upside of 25.79%. Given Seer's higher probable upside, research analysts plainly believe Seer is more favorable than Avid Bioservices.

Profitability

This table compares Seer and Avid Bioservices' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SeerN/AN/AN/A
Avid BioservicesN/AN/AN/A

Summary

Seer beats Avid Bioservices on 2 of the 2 factors compared between the two stocks.

Avid Bioservices (NASDAQ:CDMOP) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings.

Profitability

This table compares Avid Bioservices and Nuvation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Avid BioservicesN/AN/AN/A
Nuvation BioN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations for Avid Bioservices and Nuvation Bio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Avid Bioservices0000N/A
Nuvation Bio00603.00

Nuvation Bio has a consensus target price of $17.40, suggesting a potential upside of 46.10%. Given Nuvation Bio's higher possible upside, analysts plainly believe Nuvation Bio is more favorable than Avid Bioservices.

Valuation & Earnings

This table compares Avid Bioservices and Nuvation Bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avid BioservicesN/AN/AN/AN/AN/A
Nuvation BioN/AN/AN/AN/AN/A

Summary

Nuvation Bio beats Avid Bioservices on 2 of the 2 factors compared between the two stocks.

Avid Bioservices (NASDAQ:CDMOP) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Earnings and Valuation

This table compares Avid Bioservices and ImmunityBio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avid BioservicesN/AN/AN/AN/AN/A
ImmunityBioN/AN/AN/AN/AN/A

Profitability

This table compares Avid Bioservices and ImmunityBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Avid BioservicesN/AN/AN/A
ImmunityBioN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Avid Bioservices and ImmunityBio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Avid Bioservices0000N/A
ImmunityBio00103.00

ImmunityBio has a consensus target price of $25.00, suggesting a potential upside of 36.54%. Given ImmunityBio's higher probable upside, analysts clearly believe ImmunityBio is more favorable than Avid Bioservices.

Summary

ImmunityBio beats Avid Bioservices on 2 of the 2 factors compared between the two stocks.


Avid Bioservices Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AbCellera Biologics logo
ABCL
AbCellera Biologics
1.5$28.79flat$7.62 billionN/A0.00Increase in Short Interest
Sana Biotechnology logo
SANA
Sana Biotechnology
1.2$25.51flat$4.54 billionN/A0.00
Abcam logo
ABCM
Abcam
1.5$19.64flat$4.46 billionN/A0.00News Coverage
SEER
Seer
1.0$54.74flat$3.47 billionN/A0.00Increase in Short Interest
Nuvation Bio logo
NUVB
Nuvation Bio
2.2$11.89flat$2.18 billionN/A0.00Analyst Report
Insider Buying
News Coverage
Gap Down
IBRX
ImmunityBio
1.7$18.20flat$1.83 billionN/A0.00Gap Down
BioAtla logo
BCAB
BioAtla
1.7$46.69flat$1.55 billionN/A0.00News Coverage
Immunocore logo
IMCR
Immunocore
1.3$36.00flat$1.42 billionN/A0.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.5$35.29flat$1.40 billionN/A0.00
EWTX
Cricut
0.3$28.24flat$1.33 billionN/A0.00
KNTE
Kinnate Biopharma
1.7$29.32flat$1.23 billionN/A0.00Increase in Short Interest
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$38.10flat$1.19 billionN/A0.00Analyst Report
News Coverage
Gap Down
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
2.0$31.73flat$1.18 billionN/A0.00Earnings Announcement
Analyst Report
Insider Selling
Increase in Short Interest
News Coverage
Vor Biopharma logo
VOR
Vor Biopharma
1.9$31.91flat$1.08 billionN/A0.00
FDMT
4D Molecular Therapeutics
1.1$37.35flat$954.04 millionN/A0.00Increase in Short Interest
Gap Down
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
1.0$16.89flat$946.10 millionN/A0.00Analyst Report
News Coverage
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$29.30flat$918.27 millionN/A0.00Gap Down
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$13.81flat$908.70 millionN/A0.00
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$24.57flat$876.07 millionN/A0.00Analyst Report
Increase in Short Interest
PHAR
Pharming Group
0.0$12.95flat$845.43 millionN/A0.00Decrease in Short Interest
News Coverage
Gap Up
FNCH
Finch Therapeutics Group
1.3$16.45flat$801.47 millionN/A0.00Analyst Report
News Coverage
Gap Up
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$22.88flat$798.13 millionN/A0.00Analyst Report
SGTX
Sigilon Therapeutics
1.4$20.29flat$587.03 millionN/A0.00Increase in Short Interest
News Coverage
Gap Down
Inventiva logo
IVA
Inventiva
1.4$13.75flat$540.43 millionN/A0.00News Coverage
Gap Up
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$11.43flat$506.10 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Gap Up
NexImmune logo
NEXI
NexImmune
2.0$24.36flat$476.78 millionN/A0.00News Coverage
Gap Down
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$19.44flat$447.23 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.39flat$438.63 millionN/A0.00
Landos Biopharma logo
LABP
Landos Biopharma
1.8$11.20flat$425.65 millionN/A0.00News Coverage
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$15.09flat$421.33 millionN/A0.00
PRTG
Portage Biotech
0.0$28.55flat$353.43 millionN/A0.00
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$7.00flat$302.37 millionN/A-2.77
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.76flat$299.20 millionN/A-3.06Gap Down
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.61flat$259.23 millionN/A0.00
IPA
ImmunoPrecise Antibodies
0.0$11.36flat$224.46 millionN/A0.00Increase in Short Interest
Gap Up
LBPH
Longboard Pharmaceuticals
1.9$11.86flat$200.64 millionN/A0.00Analyst Report
News Coverage
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$23.94flat$167.63 millionN/A0.00
VINC
Vincerx Pharma
1.0$19.19flat$155.32 millionN/A0.00
GANX
Gain Therapeutics
1.7$13.20flat$149.57 millionN/A0.00Analyst Report
Gap Up
LGVN
Longeveron
0.3$7.45flat$136.94 millionN/A0.00News Coverage
Gap Up
EVAX
Evaxion Biotech A/S
1.7$6.96flat$124.99 millionN/A0.00News Coverage
Gap Down
UPC
Universe Pharmaceuticals
0.0$4.06flat$88.96 millionN/A0.00Gap Down
VRDN
Viridian Therapeutics
1.7$15.25flat$60.07 millionN/A0.00Decrease in Short Interest
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.43flat$54.58 millionN/A0.00Gap Up
VIRI
Virios Therapeutics
1.3$5.85flat$48.73 millionN/A0.00Gap Up
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.34flat$37.93 millionN/A0.00Gap Down
VLON
Vallon Pharmaceuticals
0.3$5.05flat$34.87 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3$4.66flat$23.39 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$38.86flat$18.25 millionN/A0.00Gap Up
VYNT
Vyant Bio
0.0$3.82flat$14.91 millionN/A0.00
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.